Allurion Technologies

ALUR · NYSE

$0.475−$0.46 (−49.20%)TodayMarket closed ·
No price history for this range.

About ALUR

Allurion Technologies, Inc. develops treatments for obesity. The company is headquartered in Natick, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-03-29. The firm offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.

Employees
40
Headquarters
Natick, Massachusetts
Listed
Mar 29, 2021
Sector
Consumer Discretionary
Industry
Diversified Consumer Services

ALUR key statistics

Market cap
475.20K
Price-earnings ratio
—
Dividend yield
—
Average volume
3.99K
Volume
162
Open price
$0.475
High today
$0.475
Low today
$0.475
52 Week high
$31.50
52 Week low
$0.40

Allurion Technologies (ALUR) at a glance

As of Oct 20, 2026, Allurion Technologies (ALUR) shares are priced at $0.475, giving the company a market cap of 475.20K.

Volume so far is 162 shares, below the average of 3.99K shares a day.

Over the past year Allurion Technologies has ranged from $0.40 to $31.50, and now sits 0% of the way up that range.

Allurion Technologies met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY26 it reported -$2.25 per share against an estimate of -$5.20.

The average analyst price target is $122.40, 25668.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $122.40
Low
$121.20
Now
$0.475
High
$126.00

ALUR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 62.7% on average.

  1. Q2 FY24: reported -$18.75 per share against an estimate of -$91.80
  2. Q3 FY24: reported -$52.50 per share against an estimate of -$69.42
  3. Q4 FY24: reported -$92.55 per share against an estimate of -$79.05
  4. Q1 FY25: reported $21.90 per share against an estimate of -$185.97
  5. Q2 FY25: reported -$19.20 per share against an estimate of -$11.94
  6. Q3 FY25: reported -$17.70 per share against an estimate of -$30.14
  7. Q4 FY25: reported -$9.90 per share against an estimate of -$9.41
  8. Q1 FY26: reported -$2.25 per share against an estimate of -$5.20

ALUR news

  • Press releaseBusiness Wire

    Allurion Advances Plan to Re-List

  • Press releaseBusiness Wire

    Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

  • 8 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseBusiness Wire

    Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

  • 12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

  • Avi Kapoor

    Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views

  • Avi Kapoor

    Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings

  • Press releaseBusiness Wire

    Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.